The University of Southampton
University of Southampton Institutional Repository

Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome

Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome
Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome

Study question: what is the recommended assessment and management of those with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference? 

Summary answer: international evidence-based guidelines address prioritized questions and outcomes and include 254 recommendations and practice points, to promote consistent, evidence-based care and improve the experience and health outcomes in PCOS. 

What is known already: the 2018 International PCOS Guideline was independently evaluated as high quality and integrated multidisciplinary and consumer perspectives from six continents; it is now used in 196 countries and is widely cited. It was based on best available, but generally very low to low quality, evidence. It applied robust methodological processes and addressed shared priorities. The guideline transitioned from consensus based to evidence-based diagnostic criteria and enhanced accuracy of diagnosis, whilst promoting consistency of care. However, diagnosis is still delayed, the needs of those with PCOS are not being adequately met, evidence quality was low and evidence-practice gaps persist. 

Study design, size, duration: the 2023 International Evidence-based Guideline update reengaged the 2018 network across professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Extensive evidence synthesis was completed. Appraisal of Guidelines for Research and Evaluation-II (AGREEII)-compliant processes were followed. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength and diversity and inclusion were considered throughout. 

Participants/materials, setting, methods: this summary should be read in conjunction with the full Guideline for detailed participants and methods. Governance included a six-continent international advisory and management committee, five guideline development groups, and paediatric, consumer, and translation committees. Extensive consumer engagement and guideline experts informed the update scope and priorities. Engaged international society-nominated panels included paediatrics, endocrinology, gynaecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, obesity care, public health and other experts, alongside consumers, project management, evidence synthesis, statisticians and translation experts. Thirty-nine professional and consumer organizations covering 71 countries engaged in the process. Twenty meetings and five face-to-face forums over 12 months addressed 58 prioritized clinical questions involving 52 systematic and 3 narrative reviews. Evidence-based recommendations were developed and approved via consensus across five guideline panels, modified based on international feedback and peer review, independently reviewed for methodological rigour, and approved by the Australian Government National Health and Medical Research Council (NHMRC). 

Main results and the role of chance: the evidence in the assessment and management of PCOS has generally improved in the past five years, but remains of low to moderate quality. The technical evidence report and analyses (∼6000 pages) underpins 77 evidence-based and 54 consensus recommendations, with 123 practice points. Key updates include: i) further refinement of individual diagnostic criteria, a simplified diagnostic algorithm and inclusion of anti-Müllerian hormone (AMH) levels as an alternative to ultrasound in adults only; ii) strengthening recognition of broader features of PCOS including metabolic risk factors, cardiovascular disease, sleep apnea, very high prevalence of psychological features, and high risk status for adverse outcomes during pregnancy; iii) emphasizing the poorly recognized, diverse burden of disease and the need for greater healthcare professional education, evidence-based patient information, improved models of care and shared decision making to improve patient experience, alongside greater research; iv) maintained emphasis on healthy lifestyle, emotional wellbeing and quality of life, with awareness and consideration of weight stigma; and v) emphasizing evidence-based medical therapy and cheaper and safer fertility management. 

Limitations, reasons for caution: overall, recommendations are strengthened and evidence is improved, but remain generally low to moderate quality. Significantly greater research is now needed in this neglected, yet common condition. Regional health system variation was considered and acknowledged, with a further process for guideline and translation resource adaptation provided. 

Wider implications of the findings: the 2023 International Guideline for the Assessment and Management of PCOS provides clinicians and patients with clear advice on best practice, based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation programme supports the Guideline with an integrated evaluation program. 

Study funding/competing interest(s): this effort was primarily funded by the Australian Government via the National Health Medical Research Council (NHMRC) (APP1171592), supported by a partnership with American Society for Reproductive Medicine, Endocrine Society, European Society for Human Reproduction and Embryology, and the Society for Endocrinology. The Commonwealth Government of Australia also supported Guideline translation through the Medical Research Future Fund (MRFCRI000266). HJT and AM are funded by NHMRC fellowships. JT is funded by a Royal Australasian College of Physicians (RACP) fellowship. Guideline development group members were volunteers. Travel expenses were covered by the sponsoring organizations. Disclosures of interest were strictly managed according to NHMRC policy and are available with the full guideline, technical evidence report, peer review and responses (www.monash.edu/medicine/mchri/pcos). Of named authors HJT, CTT, AD, LM, LR, JBoyle, AM have no conflicts of interest to declare. JL declares grant from Ferring and Merck; consulting fees from Ferring and Titus Health Care; speaker's fees from Ferring; unpaid consultancy for Ferring, Roche Diagnostics and Ansh Labs; and sits on advisory boards for Ferring, Roche Diagnostics, Ansh Labs, and Gedeon Richter. TP declares a grant from Roche; consulting fees from Gedeon Richter and Organon; speaker's fees from Gedeon Richter and Exeltis; travel support from Gedeon Richter and Exeltis; unpaid consultancy for Roche Diagnostics; and sits on advisory boards for Roche Diagnostics. MC declares travels support from Merck; and sits on an advisory board for Merck. JBoivin declares grants from Merck Serono Ltd.; consulting fees from Ferring B.V; speaker's fees from Ferring Arzneimittell GmbH; travel support from Organon; and sits on an advisory board for the Office of Health Economics. RJN has received speaker's fees from Merck and sits on an advisory board for Ferring. AJoham has received speaker's fees from Novo Nordisk and Boehringer Ingelheim. The guideline was peer reviewed by special interest groups across our 39 partner and collaborating organizations, was independently methodologically assessed against AGREEII criteria and was approved by all members of the guideline development groups and by the NHMRC.

assessment, evidence-based, GRADE, guideline, management, Polycystic ovary syndrome
0015-0282
767-793
Teede, Helena J.
772919b7-32fa-453f-a0d5-2a642a9e946a
Tay, Chau Thien
4a594a1a-1c15-45aa-bd66-455a81c0cc88
Laven, Joop
840def1a-6693-4488-b412-29794c5fc56f
Dokras, Anuja
89ea8472-73ae-4f71-9630-095b59ed7841
Moran, Lisa J.
dd83b9e4-3e70-4000-b246-4cdb97bd3f56
Piltonen, Terhi T.
829e1d0b-d05a-4ca2-b350-d02f3b1a293e
Costello, Michael F.
4bb58b80-389e-46d1-86f1-6a02b18f316f
Boivin, Jacky
635abacc-1b16-4280-ba4b-9ec691d9094a
M. Redman, Leanne
11f81afb-86ec-433f-bd34-d83bc0af4a77
A. Boyle, Jacqueline
b252a1b8-c617-4770-b1de-5c378fbb26ee
Norman, Robert J.
2a0957c9-f077-424b-a4ef-f941c79d8eeb
Mousa, Aya
6cd559aa-d397-4e22-8d94-3b7a022d7d7b
Joham, Anju E.
efe4dbe9-4d7f-489d-b554-64958a151bb3
Arlt, Wiebke
fcf7aa71-468a-4097-b2cc-a04b283e53c7
Azziz, Ricardo
a9ce2f2a-8688-4cd5-8171-23a08eb044f2
Balen, Adam
36b47dbf-408c-462f-84a5-2785f554aa21
Bedson, Lisa
364f653e-0ca4-40ca-b2d1-8698eec6501f
Berry, Lorna
6eaef834-692a-4c72-a49e-dff74ef8292e
Boyle, Jacqueline
7ea90ea4-670f-452e-a1fb-128223f69a3f
Brennan, Leah
de92a0ef-e976-4b7f-93c4-761bf2fa13b2
Brown, Wendy
f119944c-19a0-447a-a66a-1c7d1d081fb1
Burgert, Tania
66b112b7-899b-42e6-a37f-7efbd8a6ec74
Busby, Maureen
7f1d514a-c00a-4225-a4eb-b8176b4c774e
Ee, Carolyn
ec119c46-a1e5-4d71-9c34-3f83bf4cf50e
Garad, Rhonda M.
20fe41fb-4ec3-4ae6-abbe-cd4787f9e5cc
Gibson-Helm, Melanie
d346074c-551d-42fd-90f2-dcb622c5ddfa
Harrison, Cheryce
327ac5fe-3354-4201-8af1-cc31147734e0
Hart, Roger
2c52c2ce-cd3f-40b7-b64d-9bb25d6f7d49
Hopkins, Kim
7ffe85de-f6c4-4b62-becc-8a662dd700b2
Hirschberg, Angelica Lindén
d346eb87-3786-445a-b9c8-1d464806269b
Ho, Tuong
d0ec8fe7-9279-42b7-9900-f8763f0b0a92
Hoeger, Kathleen
0cf232c7-8228-448f-acb4-67d594c3a9bf
Jordan, Cailin
7365e2e9-0684-453e-94d0-89c18d4d14e3
Legro, Richard S.
a9d48637-358e-43db-bab7-1dc2caf54450
Li, Rong
9f9ca9b4-c384-4c64-ab2a-c6f96d63edd7
Lujan, Marla
f78eb39c-c580-4621-a8eb-d2cd602bd986
Ma, Ronald
ba90ea95-22d9-47d6-b654-7f8112d8219b
Mansfield, Darren
ab9d9a75-b97a-428b-947d-fcee9e1d1cc5
Marsh, Kate
b2950be1-6a47-4677-ad56-bcfa8849f860
Mocanu, Edgar
e4ec7c9e-7443-410e-9db5-f42d2138aaf4
Mol, Ben
6fc59452-d362-4a44-a6af-39207f78518c
Mormon, Rachel
f3ee216d-949f-4c68-afc0-2f8e039ee2c8
Norman, Robert
4268d76b-8b66-46a8-aa82-2ea7ad824286
Oberfield, Sharon
66db4607-7a94-48f1-92a3-48862aac28f7
Patel, Malika
bb31d694-b36f-42b6-952f-c16538f1e7fe
Pattuwage, Loyal
0148fc21-3bd2-48d9-aa33-54fe8a214d9d
Peña, Alexia
6024e539-f0af-4d07-ba36-b054cedbe3b1
Redman, Leanne
e9cb11dc-622d-47ae-90e1-4e84e0cf8339
Rombauts, Luk
f81157c3-87a8-4397-bfe0-cc7fd6c0caa7
Romualdi, Daniela
cfa613d1-3c17-4ac1-8b11-589c2c1edfbf
International PCOS Network
Teede, Helena J.
772919b7-32fa-453f-a0d5-2a642a9e946a
Tay, Chau Thien
4a594a1a-1c15-45aa-bd66-455a81c0cc88
Laven, Joop
840def1a-6693-4488-b412-29794c5fc56f
Dokras, Anuja
89ea8472-73ae-4f71-9630-095b59ed7841
Moran, Lisa J.
dd83b9e4-3e70-4000-b246-4cdb97bd3f56
Piltonen, Terhi T.
829e1d0b-d05a-4ca2-b350-d02f3b1a293e
Costello, Michael F.
4bb58b80-389e-46d1-86f1-6a02b18f316f
Boivin, Jacky
635abacc-1b16-4280-ba4b-9ec691d9094a
M. Redman, Leanne
11f81afb-86ec-433f-bd34-d83bc0af4a77
A. Boyle, Jacqueline
b252a1b8-c617-4770-b1de-5c378fbb26ee
Norman, Robert J.
2a0957c9-f077-424b-a4ef-f941c79d8eeb
Mousa, Aya
6cd559aa-d397-4e22-8d94-3b7a022d7d7b
Joham, Anju E.
efe4dbe9-4d7f-489d-b554-64958a151bb3
Arlt, Wiebke
fcf7aa71-468a-4097-b2cc-a04b283e53c7
Azziz, Ricardo
a9ce2f2a-8688-4cd5-8171-23a08eb044f2
Balen, Adam
36b47dbf-408c-462f-84a5-2785f554aa21
Bedson, Lisa
364f653e-0ca4-40ca-b2d1-8698eec6501f
Berry, Lorna
6eaef834-692a-4c72-a49e-dff74ef8292e
Boyle, Jacqueline
7ea90ea4-670f-452e-a1fb-128223f69a3f
Brennan, Leah
de92a0ef-e976-4b7f-93c4-761bf2fa13b2
Brown, Wendy
f119944c-19a0-447a-a66a-1c7d1d081fb1
Burgert, Tania
66b112b7-899b-42e6-a37f-7efbd8a6ec74
Busby, Maureen
7f1d514a-c00a-4225-a4eb-b8176b4c774e
Ee, Carolyn
ec119c46-a1e5-4d71-9c34-3f83bf4cf50e
Garad, Rhonda M.
20fe41fb-4ec3-4ae6-abbe-cd4787f9e5cc
Gibson-Helm, Melanie
d346074c-551d-42fd-90f2-dcb622c5ddfa
Harrison, Cheryce
327ac5fe-3354-4201-8af1-cc31147734e0
Hart, Roger
2c52c2ce-cd3f-40b7-b64d-9bb25d6f7d49
Hopkins, Kim
7ffe85de-f6c4-4b62-becc-8a662dd700b2
Hirschberg, Angelica Lindén
d346eb87-3786-445a-b9c8-1d464806269b
Ho, Tuong
d0ec8fe7-9279-42b7-9900-f8763f0b0a92
Hoeger, Kathleen
0cf232c7-8228-448f-acb4-67d594c3a9bf
Jordan, Cailin
7365e2e9-0684-453e-94d0-89c18d4d14e3
Legro, Richard S.
a9d48637-358e-43db-bab7-1dc2caf54450
Li, Rong
9f9ca9b4-c384-4c64-ab2a-c6f96d63edd7
Lujan, Marla
f78eb39c-c580-4621-a8eb-d2cd602bd986
Ma, Ronald
ba90ea95-22d9-47d6-b654-7f8112d8219b
Mansfield, Darren
ab9d9a75-b97a-428b-947d-fcee9e1d1cc5
Marsh, Kate
b2950be1-6a47-4677-ad56-bcfa8849f860
Mocanu, Edgar
e4ec7c9e-7443-410e-9db5-f42d2138aaf4
Mol, Ben
6fc59452-d362-4a44-a6af-39207f78518c
Mormon, Rachel
f3ee216d-949f-4c68-afc0-2f8e039ee2c8
Norman, Robert
4268d76b-8b66-46a8-aa82-2ea7ad824286
Oberfield, Sharon
66db4607-7a94-48f1-92a3-48862aac28f7
Patel, Malika
bb31d694-b36f-42b6-952f-c16538f1e7fe
Pattuwage, Loyal
0148fc21-3bd2-48d9-aa33-54fe8a214d9d
Peña, Alexia
6024e539-f0af-4d07-ba36-b054cedbe3b1
Redman, Leanne
e9cb11dc-622d-47ae-90e1-4e84e0cf8339
Rombauts, Luk
f81157c3-87a8-4397-bfe0-cc7fd6c0caa7
Romualdi, Daniela
cfa613d1-3c17-4ac1-8b11-589c2c1edfbf

Teede, Helena J., Tay, Chau Thien and Laven, Joop , International PCOS Network (2023) Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility, 120 (4), 767-793. (doi:10.1016/j.fertnstert.2023.07.025).

Record type: Article

Abstract

Study question: what is the recommended assessment and management of those with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference? 

Summary answer: international evidence-based guidelines address prioritized questions and outcomes and include 254 recommendations and practice points, to promote consistent, evidence-based care and improve the experience and health outcomes in PCOS. 

What is known already: the 2018 International PCOS Guideline was independently evaluated as high quality and integrated multidisciplinary and consumer perspectives from six continents; it is now used in 196 countries and is widely cited. It was based on best available, but generally very low to low quality, evidence. It applied robust methodological processes and addressed shared priorities. The guideline transitioned from consensus based to evidence-based diagnostic criteria and enhanced accuracy of diagnosis, whilst promoting consistency of care. However, diagnosis is still delayed, the needs of those with PCOS are not being adequately met, evidence quality was low and evidence-practice gaps persist. 

Study design, size, duration: the 2023 International Evidence-based Guideline update reengaged the 2018 network across professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Extensive evidence synthesis was completed. Appraisal of Guidelines for Research and Evaluation-II (AGREEII)-compliant processes were followed. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength and diversity and inclusion were considered throughout. 

Participants/materials, setting, methods: this summary should be read in conjunction with the full Guideline for detailed participants and methods. Governance included a six-continent international advisory and management committee, five guideline development groups, and paediatric, consumer, and translation committees. Extensive consumer engagement and guideline experts informed the update scope and priorities. Engaged international society-nominated panels included paediatrics, endocrinology, gynaecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, obesity care, public health and other experts, alongside consumers, project management, evidence synthesis, statisticians and translation experts. Thirty-nine professional and consumer organizations covering 71 countries engaged in the process. Twenty meetings and five face-to-face forums over 12 months addressed 58 prioritized clinical questions involving 52 systematic and 3 narrative reviews. Evidence-based recommendations were developed and approved via consensus across five guideline panels, modified based on international feedback and peer review, independently reviewed for methodological rigour, and approved by the Australian Government National Health and Medical Research Council (NHMRC). 

Main results and the role of chance: the evidence in the assessment and management of PCOS has generally improved in the past five years, but remains of low to moderate quality. The technical evidence report and analyses (∼6000 pages) underpins 77 evidence-based and 54 consensus recommendations, with 123 practice points. Key updates include: i) further refinement of individual diagnostic criteria, a simplified diagnostic algorithm and inclusion of anti-Müllerian hormone (AMH) levels as an alternative to ultrasound in adults only; ii) strengthening recognition of broader features of PCOS including metabolic risk factors, cardiovascular disease, sleep apnea, very high prevalence of psychological features, and high risk status for adverse outcomes during pregnancy; iii) emphasizing the poorly recognized, diverse burden of disease and the need for greater healthcare professional education, evidence-based patient information, improved models of care and shared decision making to improve patient experience, alongside greater research; iv) maintained emphasis on healthy lifestyle, emotional wellbeing and quality of life, with awareness and consideration of weight stigma; and v) emphasizing evidence-based medical therapy and cheaper and safer fertility management. 

Limitations, reasons for caution: overall, recommendations are strengthened and evidence is improved, but remain generally low to moderate quality. Significantly greater research is now needed in this neglected, yet common condition. Regional health system variation was considered and acknowledged, with a further process for guideline and translation resource adaptation provided. 

Wider implications of the findings: the 2023 International Guideline for the Assessment and Management of PCOS provides clinicians and patients with clear advice on best practice, based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation programme supports the Guideline with an integrated evaluation program. 

Study funding/competing interest(s): this effort was primarily funded by the Australian Government via the National Health Medical Research Council (NHMRC) (APP1171592), supported by a partnership with American Society for Reproductive Medicine, Endocrine Society, European Society for Human Reproduction and Embryology, and the Society for Endocrinology. The Commonwealth Government of Australia also supported Guideline translation through the Medical Research Future Fund (MRFCRI000266). HJT and AM are funded by NHMRC fellowships. JT is funded by a Royal Australasian College of Physicians (RACP) fellowship. Guideline development group members were volunteers. Travel expenses were covered by the sponsoring organizations. Disclosures of interest were strictly managed according to NHMRC policy and are available with the full guideline, technical evidence report, peer review and responses (www.monash.edu/medicine/mchri/pcos). Of named authors HJT, CTT, AD, LM, LR, JBoyle, AM have no conflicts of interest to declare. JL declares grant from Ferring and Merck; consulting fees from Ferring and Titus Health Care; speaker's fees from Ferring; unpaid consultancy for Ferring, Roche Diagnostics and Ansh Labs; and sits on advisory boards for Ferring, Roche Diagnostics, Ansh Labs, and Gedeon Richter. TP declares a grant from Roche; consulting fees from Gedeon Richter and Organon; speaker's fees from Gedeon Richter and Exeltis; travel support from Gedeon Richter and Exeltis; unpaid consultancy for Roche Diagnostics; and sits on advisory boards for Roche Diagnostics. MC declares travels support from Merck; and sits on an advisory board for Merck. JBoivin declares grants from Merck Serono Ltd.; consulting fees from Ferring B.V; speaker's fees from Ferring Arzneimittell GmbH; travel support from Organon; and sits on an advisory board for the Office of Health Economics. RJN has received speaker's fees from Merck and sits on an advisory board for Ferring. AJoham has received speaker's fees from Novo Nordisk and Boehringer Ingelheim. The guideline was peer reviewed by special interest groups across our 39 partner and collaborating organizations, was independently methodologically assessed against AGREEII criteria and was approved by all members of the guideline development groups and by the NHMRC.

Text
1-s2.0-S0015028223007197-main - Version of Record
Download (322kB)

More information

e-pub ahead of print date: 14 August 2023
Additional Information: Funding Information: The Australian National Health Medical Research Council (NHMRC) (APP1171592) primarily funded this work. The American Society for Reproductive Medicine , Endocrine Society , the European Society of Human Reproduction and Embryology and the European Society for Endocrinology provided partnership funding. Collaborating organizations provided in-kind support. The Commonwealth Government of Australia also supported Guideline Translation through the Medical Research Future Fund (MRFCRI000266). HJT and AM are funded by NHMRC fellowships and JT by an RACP fellowship.
Keywords: assessment, evidence-based, GRADE, guideline, management, Polycystic ovary syndrome

Identifiers

Local EPrints ID: 483869
URI: http://eprints.soton.ac.uk/id/eprint/483869
ISSN: 0015-0282
PURE UUID: fdfd8506-7488-405a-817a-1edf98d2e5ab

Catalogue record

Date deposited: 07 Nov 2023 17:47
Last modified: 11 Jul 2024 04:54

Export record

Altmetrics

Contributors

Author: Helena J. Teede
Author: Chau Thien Tay
Author: Joop Laven
Author: Anuja Dokras
Author: Lisa J. Moran
Author: Terhi T. Piltonen
Author: Michael F. Costello
Author: Jacky Boivin
Author: Leanne M. Redman
Author: Jacqueline A. Boyle
Author: Robert J. Norman
Author: Aya Mousa
Author: Anju E. Joham
Author: Wiebke Arlt
Author: Ricardo Azziz
Author: Adam Balen
Author: Lisa Bedson
Author: Lorna Berry
Author: Jacqueline Boyle
Author: Leah Brennan
Author: Wendy Brown
Author: Tania Burgert
Author: Maureen Busby
Author: Carolyn Ee
Author: Rhonda M. Garad
Author: Melanie Gibson-Helm
Author: Cheryce Harrison
Author: Roger Hart
Author: Kim Hopkins
Author: Angelica Lindén Hirschberg
Author: Tuong Ho
Author: Kathleen Hoeger
Author: Cailin Jordan
Author: Richard S. Legro
Author: Rong Li
Author: Marla Lujan
Author: Ronald Ma
Author: Darren Mansfield
Author: Kate Marsh
Author: Edgar Mocanu
Author: Ben Mol
Author: Rachel Mormon
Author: Robert Norman
Author: Sharon Oberfield
Author: Malika Patel
Author: Loyal Pattuwage
Author: Alexia Peña
Author: Leanne Redman
Author: Luk Rombauts
Author: Daniela Romualdi
Corporate Author: International PCOS Network

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×